INTRALIPID 20% Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Intralipid 20%, and when can generic versions of Intralipid 20% launch?
Intralipid 20% is a drug marketed by Fresenius and is included in two NDAs.
The generic ingredient in INTRALIPID 20% is soybean oil. There are thirteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the soybean oil profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for INTRALIPID 20%?
- What are the global sales for INTRALIPID 20%?
- What is Average Wholesale Price for INTRALIPID 20%?
Summary for INTRALIPID 20%
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 3 |
| Clinical Trials: | 84 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | INTRALIPID 20% at DailyMed |
Recent Clinical Trials for INTRALIPID 20%
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Rochester | Phase 2 |
| Yale University | Phase 1 |
| University of Kansas Medical Center | Early Phase 1 |
Pharmacology for INTRALIPID 20%
| Drug Class | Lipid Emulsion |
US Patents and Regulatory Information for INTRALIPID 20%
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius | INTRALIPID 20% | soybean oil | INJECTABLE;INJECTION | 018449-001 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Fresenius | INTRALIPID 20% | soybean oil | INJECTABLE;INJECTION | 020248-001 | Aug 7, 1996 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
